Head-to-head evidence
Trastuzumab Deruxtecan vs Trastuzumab rezetecan
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HR+/HER2- Metastatic Breast Cancer
Shared mechanism: HER2 · full HR+/HER2- Metastatic Breast Cancer pipeline
Trastuzumab Deruxtecan
Marketed by Daiichi Sankyo and partners
NCT03523585 · Phase 3 · completed
The 608-participant trial was randomized and actively controlled, with progression-free survival assessed by blinded independent central review as the primary clinical endpoint. The primary comparison was statistically significant in favor of trastuzumab deruxtecan, but treatment assignment was open-label rather than double-blinded, supporting a moderate evidence grade.
Next expected readout: October 2026 · NCT06429761 (registry estimate)
Trastuzumab rezetecan
Developed by Jiangsu Hengrui Pharmaceuticals
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: October 2026 · NCT06222879 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Trastuzumab Deruxtecan's landscape · Trastuzumab rezetecan's landscape